Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
icotinib + WBRT
- Development stage
- Unknown
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Icotinib + WBRT is a combination therapeutic regimen consisting of the small molecule epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) icotinib hydrochloride and concurrent whole brain radiation therapy (WBRT). Developed by Betta Pharmaceuticals, this regimen is specifically designed for patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations who have developed brain metastases. Icotinib, marketed as Conmana in China, selectively inhibits the intracellular tyrosine kinase domain of EGFR, while WBRT provides local control of intracranial lesions through ionizing radiation. Clinical studies, including Phase 3 and 4 trials, have evaluated the safety and efficacy of this combination, focusing on intracranial objective response rates and progression-free survival in patients with advanced EGFR-mutated NSCLC.
- Brand names
- Conmana
- Other names
- icotinib + whole brain radiation therapyicotinib + whole brain radiotherapyicotinib hydrochloride + WBRT
02
Targets
Beyond the preview
Go deeper on icotinib + WBRT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on icotinib + WBRT.